External broker reports(aggregated public sources), Mirae Asset Securities

Mirae Asset Securities

External broker reports(aggregated public sources)

Leading full-service brokerage firm in Vietnam. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>InBody posted in-line revenue of W56.2bn (+12% YoY), marking a record high for the sixth consecutive quarter.</li><li>Operating profit came in at W10.4bn (+10% YoY; above the consensus), with an OP margin of 18.5% (-0.2%p YoY).</li><li>By product, revenue was W45.5bn (+14% YoY) for professional-use InBody (including software), W6.9bn (-5% YoY) for consumer-use InBody (InBody Dial and InBody Band), and W3.9bn (+28% YoY) for medical devices.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

InBody posted in-line revenue of W56.2bn (+12% YoY), marking a record high for the sixth consecutive quarter.Operating profit came in at W10.4bn (+10% YoY; above the consensus), with an OP margin of 18.5% (-0.2%p YoY).By product, revenue was W45.5bn (+14% YoY) for professional-use InBody (including software), W6.9bn (-5% YoY) for consumer-use InBody (InBody Dial and InBody Band), and W3.9bn (+28% YoY) for medical devices.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

InBody (041830 KQ/Buy)Sales Force Expansion Now Complete

South Korea

InBody Co., Ltd. manufactures and markets a body composition analyzer and other related medical instruments.  The Company supplies its products to the hospitals, clinics, fitness clubs, and households.  Biospace also exports its products to overseas markets, such as America, Europe, and Asia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Inbody Co Ltd (041830 KS)

InBody (041830 KQ/Buy)Sales Force Expansion Now Complete

InBody posted in-line revenue of W56.2bn (+12% YoY), marking a record high for the sixth consecutive quarter. Operating profit came in at W10.4bn...

Mirae Asset Securities

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)